The potential for interactions between antimalarial and antiretroviral drugs

AIDS

Volumn 19, Issue 10, 2005, Pages 995-1005

  Khoo, Saye ^a   Back, David ^a   Winstanley, Peter ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATAZANAVIR; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; DIDANOSINE; DIHYDROARTEMISININ; EFAVIRENZ; EMTRICITABINE; HALOFANTRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; MEFLOQUINE; NELFINAVIR; NEVIRAPINE; PRIMAQUINE; PROGUANIL; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUININE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STAVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ; SULFADOXINE; TENOFOVIR; TETRACYCLINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; APLASTIC ANEMIA; BODY WEIGHT; COMA; DEPRESSION; DERMATITIS; DIPLOPIA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EDITORIAL; ETHNOLOGY; FEVER; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOGLYCEMIA; INSOMNIA; LACTIC ACIDOSIS; LEUKOPENIA; LIVER TOXICITY; MALARIA; METHEMOGLOBINEMIA; MYALGIA; MYOSITIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; SKIN PIGMENTATION; THROMBOCYTOPENIA; VISUAL IMPAIRMENT;

EID: 21844449462     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000174445.40379.e0     Document Type: Editorial

References (48)

1. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl 1):S5-S37.
2. Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther 2004; 9:97-101.
3. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, for the 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. 2004; 363:1253-12563.
4. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 (Suppl 5):S171-S181.
5. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
6. La Porte C, Burger D, Gyssens I, Sprenger H, Koopmans P. Gender differences in nevirapine pharmacokinetics, fact or fiction? In: Fourth International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, March 2003 [abstract 3.1].
7. Gibbons S, Robinson L, Davies G, Back DJ, Khoo SH. Is there evidence for weight-adjusted dosing of Kaletra? In: 10th Anniversary Conference of the British HIV Association. Cardiff, April 2004 [abstract P75].
8. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit AA, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51:1231-1238.
9. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
10. Haas DW, Smeaton L, Schafer R, Robbins G, Morse G, Labbe L, et al. Pharmacogenetics of long-term response to efavirenz and nelfinavir containing regimens: NWCS213, and analysis of ACTG 384. In: Twelth Conference on Retroviruses and Opportunistic Infections. Boston, February 2005 [abstract 81].
11. Wattanagoon Y, Bangchang KN, Hoggard PG, Gibbons SE, Khoo SH, Phiboonbhanakit D, et al. The pharmacokinetics of zidovudine phosphorylation in HIV positive Thai patients and healthy volunteers. Antimicrob Agents Chemother 2000; 39:1376-1378.
12. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101:4180-4185.
13. Winstanley P, Ward S, Snow R, Breckenridge A. The therapy of falciparum malaria in sub-Saharan Africa: from molecule to policy. Clin Microbiol Rev 2004; 17:612-637.
14. Bray PG, Munthin M, Ridley RG, Ward SA. Access to haematin: the basis of chloroquine resistance. Mol Pharmacol 1998; 54:170-179.
15. Boele van Hensbroek M, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89:672-676.
16. Eckstein-Ludwig U, Webb RJ, van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424:957-961.
17. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415:686-693.
18. White NJ, Miller KD, Churchill FC, Berry C, Brown J, Williams SB, et al. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319:1493-1500.
19. Winstanley PA, Edwards G, Orme ML'E, Breckenridge AM. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987; 23:1-7.
20. Winstanley PA, Coleman JW, Maggs JM, Breckenridge AM, Park BK. The toxicity of amodiaquine and its principal metabolites towards mononuclear leukocytes and granulocyte-monocyte colony forming units. Br J Clin Pharmacol 1990; 29:479-485.
21. Winstanley PA, Watkins WM, Muhia D, Szwandt S, Amukoye E, Marsh K. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 1997; 91:322-327.
22. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 2004; 363:1843-1848.
23. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 (Suppl 1):S41-S43.
24. World Health Organization. Assessment of the Safety of Artemisinin Compounds in Pregnancy. Report on Two RBM/ TDR Informal Consultations [WHO/CDS/MAL/2003]. Geneva: 2003:1094.
25. White T, Clode S, Gaunt I, Ward A, Powell C, Clark R. Developmental toxicity of the antimalarial artesunate in rats and rabbits. Birth Defect Res Part A 2004; 70:265.
26. McGready R, Cho T, Keo NK, Thwai KL, Villegas L, Looareesuwan S, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001; 33:2009-2016.
27. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Org 1995; 73:631-642.
28. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697-704.
29. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 2004; 98:261-267.
30. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51:591-600.
31. Schippers EF, Hugen PWH, den Hatigh J, Burger DM, Hoetelmans RM, Visser LG, et al. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-infected patients. AIDS 2000; 14:2794-2795.
32. Atovaquone Summary of Product Characteristics (GlaxoSmithKline). Electronic Medicines Compendium. http://emc.medicines. org.uk. Accessed 31 March 2005.
33. Emmanuel A, Gillotin C, Farinotti R. Atovaquone suspension and indinavir have minimal pharmacokinetic interactions. In: XII International Conference on AIDS. Geneva, June1998, [abstract 12384].
34. Kaletra Summary of Product Characteristics (Abbott Laboratories). Electronic Medicines Compendium. http://emc.medicines.org.uk. Accessed 31 March 2005.
35. Metroka CE, McMechan MF, Andrada R, Laubenstein LJ, Jacobus DP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med 1991; 325:737.
36. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, Rosen DH, et al. HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS 2003; 17:595-603.
37. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051-1056.
38. ter Kuile FO, Aarise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71 (Suppl 2):41-54.
39. Grimwade K, French N, Mbatha D, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004; 18:547-554.
40. Hoffman IF, Jere CS, Taylor TE, Munthali P, Dyer JR, Wirima JJ, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999; 13:487-494.
41. Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19:913-923.
42. Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004; 35:223-232.
43. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001; 20:137-140.
44. Owen A, Janneh O, Bray PG, Hartkoorn RC, Baba M, Ward SA, et al. In vitro interaction between mefloquine and saquinavir: the role of breast cancer resistance protein. In: XV International Conference on AIDS. Bangkok, July 2004 [abstract TuPeB 4588].
45. Luchters SMF, Veldhuijzen NJ, Nsanzabera D, Kankindi B, Tuyizere S, Paxton WA, et al. A phase I/I I randomised placebo controlled study to evaluate chloroquine administration to reduce HIV-1 RNA in breast milk in an HIV-1 infected breastfeeding population: the CHARGE Study. In: XV International Conference on AIDS. Bangkok, July 2004 [abstract TuPeB4499].
46. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004; 190:1998-2000.
47. Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 2003; 362:039-041.
48. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley; 2004.